These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21076344)

  • 1. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.
    Giammarile F; Billotey C; Lombard-Bohas C; Le Bars D; Bournaud C; Masson S; Walter T; Houzard C; Scoazec JY; Hervieu V; Vuillez JP; Cornu C; Janier M; Borson-Chazot F
    Nucl Med Commun; 2011 Feb; 32(2):91-7. PubMed ID: 21076344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.
    Kameyama R; Yamamoto Y; Izuishi K; Takebayashi R; Hagiike M; Murota M; Kaji M; Haba R; Nishiyama Y
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):382-8. PubMed ID: 18985344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours.
    Herrmann K; Erkan M; Dobritz M; Schuster T; Siveke JT; Beer AJ; Wester HJ; Schmid RM; Friess H; Schwaiger M; Kleeff J; Buck AK
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):846-51. PubMed ID: 22278320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
    Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G
    Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients.
    Johnbeck CB; Knigge U; Langer SW; Loft A; Berthelsen AK; Federspiel B; Binderup T; Kjaer A
    J Nucl Med; 2016 Dec; 57(12):1851-1857. PubMed ID: 27469355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
    Baumann T; Rottenburger C; Nicolas G; Wild D
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Usefulness of
    Rinzivillo M; Partelli S; Prosperi D; Capurso G; Pizzichini P; Iannicelli E; Merola E; Muffatti F; Scopinaro F; Schillaci O; Salgarello M; Falconi M; Delle Fave G; Panzuto F
    Oncologist; 2018 Feb; 23(2):186-192. PubMed ID: 29118267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
    Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
    J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
    Ambrosini V; Tomassetti P; Castellucci P; Campana D; Montini G; Rubello D; Nanni C; Rizzello A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1431-8. PubMed ID: 18418596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
    van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT
    J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer.
    Been LB; Hoekstra HJ; Suurmeijer AJ; Jager PL; van der Laan BF; Elsinga PH
    Oral Oncol; 2009 Dec; 45(12):e211-5. PubMed ID: 19692292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer.
    Francis DL; Visvikis D; Costa DC; Arulampalam TH; Townsend C; Luthra SK; Taylor I; Ell PJ
    Eur J Nucl Med Mol Imaging; 2003 Jul; 30(7):988-94. PubMed ID: 12739071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen.
    Adams S; Baum RP; Hertel A; Schumm-Dräger PM; Usadel KH; Hör G
    Nucl Med Commun; 1998 Jul; 19(7):641-7. PubMed ID: 9853344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
    Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
    Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG-PET/CT: a retrospective chart review.
    Haidar M; Al Mahmasani L; Chehade L; Elias C; El Jebai M; Temraz S; Charafeddine M; Al Darazi M; Shamseddine A
    Nucl Med Commun; 2023 Jun; 44(6):471-479. PubMed ID: 36897058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis.
    Herrmann K; Ott K; Buck AK; Lordick F; Wilhelm D; Souvatzoglou M; Becker K; Schuster T; Wester HJ; Siewert JR; Schwaiger M; Krause BJ
    J Nucl Med; 2007 Dec; 48(12):1945-50. PubMed ID: 18006614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose.
    Yamamoto Y; Nishiyama Y; Ishikawa S; Gotoh M; Bandoh S; Kanaji N; Asakura M; Ohkawa M
    J Comput Assist Tomogr; 2008; 32(3):432-7. PubMed ID: 18520552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.